Patents by Inventor Oliver-Martin Fischer
Oliver-Martin Fischer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230053411Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 9, 2021Publication date: February 23, 2023Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Publication number: 20230013419Abstract: The present invention covers P2X3 inhibitor compounds of general formula (I) in which R1 and R2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 25, 2020Publication date: January 19, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Antje ROTTMANN, Oliver Martin FISCHER, Kai THEDE, Simon Anthony HERBERT, Ursula GANZER, Andrea ROTGERI, Elisabeth POOK
-
Publication number: 20220249458Abstract: The present invention is related to agonist of adiponectin receptor 1 (AdipoR1) and/or adiponectin receptor 2 (AdipoR2) for the treatment and/or prevention of polycystic ovary syndrome (PCOS).Type: ApplicationFiled: March 30, 2020Publication date: August 11, 2022Inventors: Bernd ELGER, Martin FRITSCH, Oliver Martin FISCHER, Ralf LESCHE
-
Patent number: 11319324Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 18, 2018Date of Patent: May 3, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
-
Publication number: 20210317128Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 18, 2018Publication date: October 14, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
-
Patent number: 11142523Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 1, 2019Date of Patent: October 12, 2021Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20210220357Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fiber sensitization, and/or other pathological conditions associated with autonomic imbalance caused by increased chemoreceptor sensitivity, in particular for the treatment of breathing disorders, Cheyne Stokes respiration, central and obstructive sleep apnea, cardiovascular disease, hypertension, resistant hypertension, and heart failure, which are related to increased activity of P2X3 receptors.Type: ApplicationFiled: May 14, 2019Publication date: July 22, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Lucas Hudson HOFMEISTER, Oliver Martin FISCHER
-
Publication number: 20210220358Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fibre sensitization, in particular for treatment and prophylaxis of Chronic Cough (CC), Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disorder (COPD), and asthma.Type: ApplicationFiled: May 14, 2019Publication date: July 22, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Christian FRIEDRICH, Isabella GASHAW, Damian BROCKSCHNIEDER, Oliver Martin FISCHER
-
Publication number: 20200131169Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 1, 2019Publication date: April 30, 2020Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Patent number: 10472354Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 15, 2018Date of Patent: November 12, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20190185466Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 15, 2018Publication date: June 20, 2019Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Patent number: 10202369Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 21, 2017Date of Patent: February 12, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Patent number: 10183937Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 21, 2017Date of Patent: January 22, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Patent number: 10174016Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: December 7, 2015Date of Patent: January 8, 2019Assignee: BEYER AKTIENGESELLSCHAFTInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20180118731Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 7, 2015Publication date: May 3, 2018Applicant: BAYER AKTIENGESELLSCHAFTInventors: Adam DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Joanna NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO
-
Publication number: 20180093980Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 21, 2017Publication date: April 5, 2018Inventors: Adam James DAVENPORT, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho
-
Publication number: 20180072713Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 21, 2017Publication date: March 15, 2018Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO
-
Patent number: 9714266Abstract: The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.Type: GrantFiled: February 18, 2014Date of Patent: July 25, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Matthias Busemann, Naomi Barak, Andrea Rotgeri, Oliver Martin Fischer, Tobias Marquardt
-
Patent number: 9512169Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.Type: GrantFiled: July 5, 2013Date of Patent: December 6, 2016Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Matthias Busemann, Oliver Martin Fischer, Naomi Barak, Andrea Rotgeri, Tobias Marquardt, Christian Stegmann
-
Patent number: 9487554Abstract: The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.Type: GrantFiled: September 24, 2012Date of Patent: November 8, 2016Assignees: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Ulrich Bothe, Naomi Barak, Matthias Busemann, Oliver Martin Fischer, Andrea Rotgeri, Isabella Gashaw, Ingo Hartung, Tobias Marquardt